Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474834 · ClinicalTrials.gov registry record
Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study
A clinical trial of Breast Cancer, sponsored by Mayo Clinic.
- Active
- Registry status
- 737
- Enrollment target
- 5
- Study locations
NCT04474834: Active study of Breast Cancer, sponsored by Mayo Clinic.
NCT04474834 is a study of Breast Cancer that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 737 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474834, a study of Breast Cancer, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 737 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will aid women at risk of breast cancer in making a decision to take (or not take) medications to prevent breast cancer.
Conditions Studied
Interventions
- GENETIC Polygenic Risk Score
Study Locations (5)
Arizona
- Mayo Clinic - Scottsdale
Florida
- Mayo Clinic - Jacksonville
Illinois
- Northwestern University - Evanston
Minnesota
- Mayo Clinic in Rochester - Rochester
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 737 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2029-12-15 |
What the registry record for NCT04474834 still lists
NCT04474834 is an observational study that tracks outcomes without assigning an intervention. The registered 737 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Polygenic Risk Score is the first listed.
NCT04474834 lists 5 locations in 5 states (Arizona, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT04474834 about?
NCT04474834 is a clinical study titled "Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study". The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will aid women at risk of breast cancer in making a decision to take (or not take) medications to preve...
What is the current status of trial NCT04474834?
This trial is currently active not recruiting. The enrollment target is 737 participants. The study started on 2019-10-17. Estimated completion is 2029-12-15.
What conditions does trial NCT04474834 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04474834?
The interventions under investigation include: Polygenic Risk Score (GENETIC).
Who is sponsoring clinical trial NCT04474834?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04474834 being conducted?
This trial has 5 study locations across Arizona, Florida, Illinois, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04474834's enrollment target sits among peer trials
737 153rd of 1224 higher than 1,072 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796141 · 736 participants · NA
Becoming United in Lifestyle Decisions
- NCT03723928 · 739 participants · NA
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI